garetosmab · Pasatru

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Fibrodysplasia Ossificans Progressiva (label: Adults with FOP: reduces new heterotopic ossification lesions and flare-ups)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Obesity · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Fibrodysplasia Ossificans Progressiva
NCT04577820 · Regeneron Pharmaceuticals
2021-10-13 – 2022-10-08 · Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)
What this study did
Phase 2 (3)
Fibrodysplasia Ossificans Progressiva
NCT03188666 · Regeneron Pharmaceuticals
2018-02-26 – 2021-09-16 · Fibrodysplasia Ossificans Progressiva
What this study did
Obesity
Other / comorbidity
NCT03710941 · Regeneron Pharmaceuticals
2019-02-19 – 2020-11-05 · Sporadic Inclusion Body Myositis
What this study did
Phase 1 (3)
Obesity
NCT06970405 · Regeneron Pharmaceuticals
2025-05-29 – 2026-06-08 · Obesity
What this study did
Other / comorbidity
NCT02943239 · Regeneron Pharmaceuticals
2016-12-08 – 2019-04-30 · Healthy Volunteers
What this study did
NCT02870400 · Regeneron Pharmaceuticals
2016-07 – 2017-01-12 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Fibrodysplasia Ossificans Progressiva: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Garetosmab (Pasatru): this drugApprovedMonoclonal antibodyActivin AReliable signal
NCT05394116: OPTIMA (NCT05394116), primary endpoint new HO lesions by whole-body CT at week 56: 94% reduction with garetosmab 3 mg/kg vs placebo; 90% reduction with garetosmab 10 mg/kg vs placebo
AndecaliximabPhase 2/3Monoclonal antibodyMatrix metalloproteinase 9 (MMP-9), Matrix metalloproteinase-9 (MMP-9)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pasatru (garetosmab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
July 2030 (1)
Phase 3Fibrodysplasia Ossificans ProgressivaNot yet recruiting
Est. primary completion 2030-07-08 · NCT07559513 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 August 2026ApprovalFDA approves Pasatru (garetosmab-grts) for FOP
US, FDA · Source ↗
August 2026FDA action dateFDA target action date August 2026
US, FDA · Source ↗
19 February 2026Filing acceptedFDA accepts the garetosmab BLA in FOP and grants Priority Review
US, FDA · Regeneron Pharmaceuticals · Source ↗
19 February 2026Priority reviewPriority Review granted for garetosmab BLA
US, FDA · Source ↗